^
    Back
    Association details:
    Biomarker:KIAA1549-BRAF fusion
    Cancer:Soft Tissue Sarcoma
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) +
    Torisel (temsirolimus) (mTOR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Int J Cancer
    Title:

    The distribution of BRAF gene fusions in solid tumors and response to targeted therapy

    Excerpt:
    A malignant spindle cell tumor of the chest wall treated as a soft tissue sarcoma featured a KIAA1549‐BRAF fusion (Fig. ​(Fig.5)5) and responded to treatment with the pan‐kinase inhibitor sorafenib in combination with bevacizumab and temsirolimus.
    DOI:
    10.1002/ijc.29825